![Page 1: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/1.jpg)
Patients receiving bisphosphonates should not take holidays from treatment
Steve Cummings
![Page 2: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/2.jpg)
Richard likes holidays
![Page 3: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/3.jpg)
Sri Lanka
Scotland
China
![Page 4: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/4.jpg)
For tourists, holidays are fun!
![Page 5: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/5.jpg)
For patients taking bisphosphonates drug holidays are dangerous
![Page 6: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/6.jpg)
The evidence
![Page 7: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/7.jpg)
A randomized trial of holidays
The FLEX Trial*
*Similar conclusions for Zoledronate from the HORIZON extension trial
![Page 8: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/8.jpg)
FLEX
• 1099 women who received 4-5 years of alendronate
• Randomized to stop or continue to 10 years
Black et al. JAMA 2008;296:1671
![Page 9: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/9.jpg)
Taking a holiday caused hip bone loss
Black et al. JAMA 2008;296:1671
![Page 10: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/10.jpg)
A holiday caused rapid hip bone loss
• Stopped alendronate after 4-5 years
• On average, lost 3.6% of total hip BMD in 5 years
• 29% lost >5%!• Some lost >10%• Could not predict
who would lose
-15 -10 -5Lost BMD
McNabb, et al. JBMR 2013;28:1319–1327
![Page 11: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/11.jpg)
A holiday increased bone resorption to pretreated levels
Black et al. JAMA 2008;296:1671
![Page 12: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/12.jpg)
A holiday increased bone resorption to pretreated levels
Bone structure deteriorates
Black et al. JAMA 2008;296:1671
![Page 13: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/13.jpg)
A holiday increased the risk of clinical vertebral fracture
Continue Holiday0
1
2
3
4
5
6 5.5%
2.5%
Black et al. JAMA 2008;296:1671
![Page 14: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/14.jpg)
A holiday increased the risk of clinical vertebral fracture
Continue Holiday0
1
2
3
4
5
6 5.5%
2.5%
Black et al. JAMA 2008;296:1671
2.9% difference in riskNNT for 5 years = 38
![Page 15: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/15.jpg)
Clinical vertebral fractures cause at least as many days of disability as hip fractures
All types Clinical spine Hip Wrist
110
149 140
78
Days of limited activity
Based on diaries of women in the placebo groups of the FIT trialFink et al. Osteoporos Int 2003;14: 69–76
![Page 16: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/16.jpg)
Holidays may cause disability
For 1000 patients in FLEX• Overall, a 5-year holiday• Caused 30 clinical vertebral fractures• Caused about 12 years (4,500 days) of disability• Prevented by continuing alendronate
![Page 17: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/17.jpg)
A holiday increased the risk of clinical vertebral fractures regardless of BMD
Schwartz et al. JBMR 2010;25:976-82
![Page 18: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/18.jpg)
Treat 81 to prevent a clinical vertebral fracture
Even in patients with hip T-scores >-2.0
Schwartz et al. JBMR 2010;25:976-82
![Page 19: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/19.jpg)
Holidays may cause disability
For 1000 “low risk” patients in FLEX• A holiday caused • 12 clinical vertebral fractures• About 5 years (~1,800 days) of disability.• Prevented by continuing alendronate
![Page 20: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/20.jpg)
What’s the harm of continuing treatment?
Atypical femoral fractures (AFFs)
![Page 21: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/21.jpg)
Atypical femoral fractures (AFF)
![Page 22: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/22.jpg)
Fear of AFFs
![Page 23: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/23.jpg)
Schilcher et al. (NEJM, 2011)
AFFs are extremely rare
Only 1 AFF for every 200 hip fractures
![Page 24: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/24.jpg)
Relative and absolute risk
First, a refresher
![Page 25: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/25.jpg)
Average annual risks of dying in the UK
Plane crash
Car crash
http://www.economist.com/blogs/gulliver/2015/01/air-safety
![Page 26: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/26.jpg)
Relative risk
Plane crash 1
Car crash 100
http://www.economist.com/blogs/gulliver/2015/01/air-safety
Average annual risks of dying in the UK
![Page 27: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/27.jpg)
Relative risk
Plane crash 1
Car crash 100
Should you stop driving?
http://www.economist.com/blogs/gulliver/2015/01/air-safety
Average annual risks of dying in the UK
![Page 28: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/28.jpg)
Relative risk Absolute risk
Plane crash 1 1 / 3,500,000
Car crash 100 1 / 35,000
Should you stop driving?
http://www.economist.com/blogs/gulliver/2015/01/air-safety
Average annual risks of dying in the UK
![Page 29: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/29.jpg)
Most rigorous studies• Large studies• X-ray confirmation• Definitions related to ASBMR criteria
Studies of the risk of AFF with long-term use
![Page 30: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/30.jpg)
Risk of AFF with long-term use
Schilcher, • Women & men 55+ y.o. with a femoral fracture • Radiographs of femoral fracture for 5,342• 172 patients had AFFs by ASBMR criteria. • Bisphosphonate use from national registry
Schilcher, et al. NEJM 2014;371:974-5
![Page 31: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/31.jpg)
Risk of AFF with long-term use
<1 ≤1-2 ≤2-3 ≤3-4 ≤4-50
20
40
60
80
100
120
1.7 8.2
28.739.7
116.4Relative Risk of AFF
Schilcher, et al. NEJM 2014;371:974-5
![Page 32: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/32.jpg)
<1 ≤1-2 ≤2-3 ≤3-4 ≤4-50
0.0010.0020.0030.0040.0050.0060.0070.0080.009
0.01
0.00002 0.00008 0.0003 0.0004 0.001
Absolute Risk of AFF
Schilcher, et al. NEJM 2014;371:974-5
1%
1.1/1,000
Risk of AFF with long-term use
![Page 33: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/33.jpg)
If a patient stops bisphosphonate...
• “70% reduction” in risk of AFF• From 11/10,00 to 3/10,000• From rare to rare
Schilcher, et al. NEJM 2014;371:974-5
![Page 34: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/34.jpg)
Dell• Kaiser Health System: ~1.8 million patients• Women & men 45+ y.o. with a femur fracture • Radiographs for 5,342• 142 patients had AFFs by ASBMR criteria. • Bisphosphonate use from pharmacy records
Dell, et al. JBMR 2012;27:2544-50
Risk of AFF with long-term use
![Page 35: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/35.jpg)
for age
1/1,000 for 10+ years
Dell, et al. JBMR 2012;27:2544-50
Absolute risk of AFF with long-term use
![Page 36: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/36.jpg)
Summary so far
In 1,000 patients taking alendronateCompared with continuing treatment, taking a 5 year holiday–Causes 30 clinical vertebral fractures–Prevents 5 cases of AFF
![Page 37: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/37.jpg)
Randomized trial of a 3 year holiday from zoledronate (Zoliday)
• Zoledronate is used by <10% • 1233 randomized to stop after 3 or continue 3
more• A 3-year holiday caused 1.5% loss of FN BMD
and 2.1% loss of L-spine BMD– ~50% will lose more, not predictable
Black et al. JBMR 2012;27:243–254
![Page 38: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/38.jpg)
A 3-year Zoliday caused
2-fold increased risk of radiographicvertebral fracture (NNT = 30)
Zoliday Continue
6.2%
3.0%
Cum
ulati
ve %
inci
denc
e o
f ver
tebr
al fr
actu
re
Black et al. JBMR 2012;27:243–254
Very limited data about other outcomes
![Page 39: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/39.jpg)
Effect of holidays from alendronate on nonvertebral fractures?
• FLEX was not designed and did not have statistical power to detect an important reduction in risk of nonvertebral fractures.
• No power to determine whether continuing treatment reduced the risk of hip fracture
(95% CI, 0.76-1.32)
![Page 40: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/40.jpg)
Stronger evidence
• 61,990 alendronate users in Denmark• 2465 took alendronate for 10+ years with high
adherence (MPR ≥ 0.80)• 2 nested case-control studies to estimate the
effect of alendronate on fracture risk• Studied subtrochanteric and femoral shaft
fractures (3 to 38% are AFFs)• Adjusted for many potential confounders
Bo Abrahamsen… Richard Eastell. BMJ 2016;353:i3365d
![Page 41: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/41.jpg)
Evidence from Dr. Eastell et al.Continuing alendronate for >5 or ≥10 years
reduces hip fracture by an ~25%
Bo Abrahamsen… Richard Eastell. BMJ 2016;353:i3365
![Page 42: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/42.jpg)
Hip fracturesST/FS fractures
During 10+ years, the rate of ST/FS fractures remained much lower than hip fracture
![Page 43: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/43.jpg)
In 1,000 patients taking alendronate for 5 years
Compared with continuing for 5 more years, a holiday would • cause 26 hip fractures• prevent 1 ST/FS fracture (<1 AFF)
*NNT for 5+ years = 38Based on Bo Abrahamsen… Richard Eastell. BMJ 2016;353:i3365
![Page 44: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/44.jpg)
Dr. Eastell concluded
“The findings support a good benefit : risk with alendronate in terms of bone health for over 10 years of continuous use.”
Bo Abrahamsen… Richard Eastell. BMJ 2016;353:i3365
![Page 45: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/45.jpg)
Your choiceVote for Richard Or vote for Dr. Eastell
For the motion Against the motion
Richard the tourist Dr. Eastell, the esteemed evidence-based clinical scientist
![Page 46: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/46.jpg)
Rebuttal
![Page 47: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/47.jpg)
Other problems with holidays
• Holidays from treatment creates a mistaken impression that treatment is bad
• If patients expect holidays, those who need to continue will be very disappointed
• If patients take a holidays, they may never come back
![Page 48: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/48.jpg)
Zoledronate
• >90% of patients receive alendronate• Arguments about zoledronate apply to <10%
of patients
![Page 49: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/49.jpg)
3- year Zoliday
• Confidence intervals are very wide for– Nonvertebral (0.7 to 1.5), – Clinical vertebral (0.5 to 6.2)– Hip 0.3 to 2.5).
• We need a much large study (in Denmark) – Expect a similar result as alendronate: significant
reductions in hip fracture for 10+ years
![Page 50: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/50.jpg)
High risk patients taking zoledronate
• Total hip T-score <-2.5 indicates a higher risk of vertebral and nonvertebral fractures
• Greater absolute reductions in risk of vertebral fractures
• For moderate risk patients, very wide confidence intervals– Decreased risk of vertebral fracture with TH >-2.5:
0.79 (0.3 to 2.5)• Too little data for nonvertebral and hip fracture
Cosman et al. J Clin Endocrinol Metab 2014; 99: 4546–4554
![Page 51: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/51.jpg)
Uncertainty about Zolidays
• We said: “after 3 years of annual ZOL, many patients may discontinue therapy up to 3 years.”
• Based on very little data, especially in moderate risk patients.
• A lot of uncertainty and, therefore, zolidays are risky
![Page 52: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/52.jpg)
IOF Epidemiology/Quality of Life Working Group
• Voted on appropriateness of bisphosphonate holidays
• The voting revealed considerable controversy globally and a lack of consensus on identification, management, and monitoring of antiresorptive holidays.
Silverman et al. IOF Epidemiology/Quality of Life Working Group.Osteoporos Int (2016) 27:849–852
![Page 53: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/53.jpg)
IOF Epidemiology/Quality of Life Working Group
• Taking account of ONJ• Women with T-score <-2.5 or a vertebral
fracture, prevent 7 to 35 clinical vertebral fracture for every event of ONJ or AFF
• “… a postive risk/benefit ratio for high risk women.”
Silverman et al. IOF Epidemiology/Quality of Life Working Group.Osteoporos Int (2016) 27:849–852
![Page 54: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/54.jpg)
The case against holidays
Holidays • Cause substantial hip bone loss • Increase bone resorption• Increase the risk of clinical vertebral fractures – With substantial disability
• Increase the risk of hip fractureAll prevented by continuing treatment• Outweighs a very rare risk of AFF
![Page 55: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/55.jpg)
The case against holidays
Holidays • Cause substantial hip bone loss • Increase bone resorption• Increase the risk of clinical vertebral fractures – With substantial disability
• Increase the risk of hip fractureAll prevented by continuing treatment• Outweighs a very rare risk of AFFVery limited data makes Zolidays risky
![Page 56: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/56.jpg)
Thank you
![Page 57: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/57.jpg)
Financial Disclosures
• Consultant to Amgen, Radius, Merck• United Airlines– Has given me 1.8 million award miles to use for
holidays
![Page 58: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/58.jpg)
No increase in subtrochanteric/femoral shaft (ST/FS) fractures with 10+ years
AFF’s are 3 to 38% of ST/FS fractures
![Page 59: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/59.jpg)
A limitation of the Abrahamsen…Eastell study
• No radiographs for AFFs• The study used ST/FS fractures, not AFFs• “Even in the worst case scenario (100% of
ST/FS are atypical and secondary to bisphosphonate use…) the number of atypical femur fractures remains too low to offset the benefits on hip fracture in patients with long term alendronate use up to 10 years.”
Bo Abrahamsen… Richard Eastell. BMJ 2016;353:i3365
![Page 60: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/60.jpg)
Does the risk of AFF increase with longer use?
for age
No reason to ‘adjust for age’ because there was no association of incidence of AFF with age
Dell, et al. JBMR 2012;27:2544-50
![Page 61: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/61.jpg)
Denosumab
• Bone mass continues to improve• Vertebral fracture risk remains low on
treatment• A ‘holiday’ increases vertebral fracture risk to
untreated levels• Increased risk of multiple vertebral fractures• Happens within 3 months of skipping a
scheduled dose.
![Page 62: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/62.jpg)
Benefit of treatment on risk of vertebral fractures is lost quickly after omitting a
scheduled dose
Cummings, unpublished
Median time off: 3 mo.s
![Page 63: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/63.jpg)
Benefit of treatment on risk of vertebral fractures is lost quickly after omitting a
scheduled dose
Cummings, unpublished
![Page 64: Osteoporosis 2016 | Patients receiving bisphosphonates should not take holidays from treatment: Dr Steve Cummings #osteo2016](https://reader036.vdocuments.net/reader036/viewer/2022081520/5871f3931a28ab5c348b6051/html5/thumbnails/64.jpg)
Denosumab
• Holidays are dangerous!• Continue denosumab or immediately switch
to a bisphosphonate.